RayKnowChina Research Map
Shortlist0

RecruitingIgG4-related diseasePhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

An open trial on IgG4-related disease, registered on ClinicalTrials.gov. Led by Peking Union Medical College Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking Union Medical College Hospital北京协和医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07068165, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with active disease: For patients with initial treatment or relapse after drug withdrawal, active disease is defined as having an IgG4-RD Response Index (RI) of at least 2 points in at least one organ at the time of screening; for those experiencing relapse while on treatment, active disease is defined as having an IgG4-RD RI of at least 3 points in at least one organ at the time of screening;

    Inclusion criterion 2

  3. Absolute neutrophil count <1.5×10\^9 /L or platelet count <100×10\^9/L;

    Exclusion criterion 2

    Creatinine clearance less than 60 ml/ min;

    Exclusion criterion 3

  4. Patients who have no plans for pregnancy within the next 18 months and who agree to use reliable contraceptive measures during the study period;

    Inclusion criterion 4

    Pregnant or lactating women;

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07068165, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients aged between 18 and 75 years who meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for IgG4-RD;
  • Patients with active disease: For patients with initial treatment or relapse after drug withdrawal, active disease is defined as having an IgG4-RD Response Index (RI) of at least 2 points in at least one organ at the time of screening; for those experiencing relapse while on treatment, active disease is defined as having an IgG4-RD RI of at least 3 points in at least one organ at the time of screening;
  • Patients with the clinical subtype of proliferative IgG4-RD;
  • Patients who have no plans for pregnancy within the next 18 months and who agree to use reliable contraceptive measures during the study period;

Exclusion Criteria:

  • IgG4-RD patients with only fibrotic features;
  • Absolute neutrophil count <1.5×10\^9 /L or platelet count <100×10\^9/L;
  • Creatinine clearance less than 60 ml/ min;
  • Liver function Child-Pugh grade B or above;
  • Chronic active infection requiring systemic treatment;
  • Diagnosed with malignant tumor in the past five years;
  • Patients with a history of thrombosis;
  • Using biological agents within six months;
  • Known to be allergic to lenalidomide or thalidomide;
  • Pregnant or lactating women;
  • Patients with any other medical conditions or for specific reasons judged by the investigator to be ineligible to participate in the study.

Quoted from ClinicalTrials.gov, NCT07068165, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07068165, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07068165